Jamjoom Pharmaceuticals Factory Company SJSC banner
J

Jamjoom Pharmaceuticals Factory Company SJSC
SAU:4015

Watchlist Manager
Jamjoom Pharmaceuticals Factory Company SJSC
SAU:4015
Watchlist
Price: 156 SAR 4.7% Market Closed
Market Cap: ﷼10.9B

Cash Flow Statement

Cash Flow Statement
Jamjoom Pharmaceuticals Factory Company SJSC

Rotate your device to view
Cash Flow Statement
Currency: SAR
Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024 Sep-2024 Dec-2024 Mar-2025 Jun-2025 Sep-2025 Dec-2025
Operating Cash Flow
Net Income
269
353
316
337
354
371
383
434
463
475
493
Depreciation & Amortization
25
32
27
28
31
34
37
40
41
42
44
Other Non-Cash Items
83
98
27
48
44
36
55
40
31
33
22
Cash Taxes Paid
32
32
16
0
21
21
21
0
23
23
23
Cash Interest Paid
0
0
0
0
0
0
0
0
0
1
1
Change in Working Capital
(170)
(234)
(74)
(133)
(166)
(131)
(212)
(210)
(229)
(192)
(153)
Cash from Operating Activities
208
N/A
249
+20%
296
+19%
279
-6%
264
-6%
310
+18%
263
-15%
304
+16%
305
+0%
359
+18%
406
+13%
Investing Cash Flow
Capital Expenditures
(46)
(63)
(45)
(54)
(62)
(55)
(57)
(48)
(57)
(60)
(66)
Other Items
(1)
(32)
(32)
(32)
(36)
(5)
(5)
(9)
(4)
(7)
(2)
Cash from Investing Activities
(47)
N/A
(95)
-102%
(77)
+19%
(86)
-11%
(98)
-14%
(61)
+38%
(62)
-2%
(57)
+9%
(61)
-7%
(67)
-10%
(69)
-3%
Financing Cash Flow
Net Issuance of Debt
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(0)
(1)
(1)
(1)
Cash Paid for Dividends
0
(70)
(70)
0
(175)
(217)
(217)
(319)
(214)
(242)
(242)
Other
(88)
0
0
0
0
0
0
0
0
0
0
Cash from Financing Activities
(88)
N/A
(158)
-80%
(70)
+55%
(70)
0%
(175)
-149%
(217)
-24%
(217)
+0%
(319)
-47%
(215)
+33%
(243)
-13%
(243)
0%
Change in Cash
Effect of Foreign Exchange Rates
(2)
(2)
(5)
(6)
(4)
(6)
(6)
(1)
(2)
1
2
Net Change in Cash
71
N/A
(6)
N/A
143
N/A
117
-18%
(14)
N/A
26
N/A
(23)
N/A
(73)
-223%
27
N/A
50
+85%
96
+91%
Free Cash Flow
Free Cash Flow
162
N/A
185
+14%
251
+35%
225
-10%
201
-11%
255
+27%
206
-19%
256
+24%
248
-3%
298
+20%
340
+14%
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett